MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ANGLE plc Company Profile (LON:AGL)

Consensus Ratings for ANGLE plc (LON:AGL) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A

Analysts' Ratings History for ANGLE plc (LON:AGL)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2015Cenkos Securities LtdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for ANGLE plc (LON:AGL)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for ANGLE plc (LON:AGL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for ANGLE plc (LON:AGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ANGLE plc (LON:AGL)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for ANGLE plc (LON:AGL)
DateHeadline
04/18/16 06:00 AMANGLE's Parsortix System Demonstrates Broader Ability to Capture Circulating Tumor Cells Versus Other Separation Technologies - [Business Wire] - A rigorous evaluation by researchers at University Medical Centre Hamburg-Eppendorf of ANGLE’s ParsortixTM cell separation system has demonstrated significant advantages of its size and deformability based enrichment technology, versus marker-based systems.
04/13/16 08:00 AMANGLE's Parsortix System Aids Important Findings Presented in Five Posters at AACR Annual Meeting April 16-20 - [Business Wire] - ANGLE plc announces that its Parsortix cell separation system will be featured in five different poster presentations at the American Association for Cancer Research Annual Meeting to be held April 16-20 in New Orleans.
03/09/16 09:45 AMANGLE plc ("the Company") European Patent Grant For Parsortix - [PR Newswire] - GUILDFORD, England, March 9, 2016 /PRNewswire/ -- ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that it has been granted a European patent for its Parsortix liquid biopsy system, which harvests cancer cells from blood for medical analysis. Recently the liquid biopsy market has been identified by several major US investment banks as an emerging multi-billion dollar market.
01/28/16 12:15 PMAngle expects "deluge of news" in months ahead as Parsortix makes progress - Andrew Newland, chief executive officer at Angle PLC (LON:AGL), tells Proactive Investors the latest interim release marks six months of "consistent progress" against the company's strategy. He says he hopes Angle will be the first company authorised by ...
01/28/16 12:15 PMAngle PLC (AGL) - ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces its unaudited interim financial results for the six months ended 31 October 2015. The Company is focused on commercialising its patented Parsortix TM liquid biopsy ...
01/25/16 06:00 AMANGLE’s Parsortix System Demonstrates Notable Performance in the Capture of Circulating Tumor Cells Versus Other Separation Technologies - [Business Wire] - A rigorous evaluation by researchers at University Medical Centre Hamburg-Eppendorf published in the International Journal of Cancer today of ANGLE’s ParsortixTM cell separation system demonstrated significant advantages of its size and deformability based enrichment technology, versus marker-based and filtration enrichment systems.
12/15/15 06:00 AMParsortix First Commercial Sales - [PR Newswire] - GUILDFORD, England, Dec. 15, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that first research use sales of the Parsortix system have been secured in line with the strategy set out in the Company's Preliminary Results on 23 July 2015. The Company estimates that the addressable market for research use sales for Parsortix is c. Where successful, this work may lead to the Parsortix system being adopted for new clinical applications and companion diagnostics (diagnostic tests to determine whether a cancer drug will benefit a patient). Widespread use of Parsortix in research is thus an important element in growing the overall market for ANGLE as well as being economically beneficial in its own right.
09/28/15 07:49 AMANGLE plc ("the Company") Poster Publication At ESMO On Use Of Parsortix System With Ovarian Cancer Patients - [PR Newswire] - The 65 patient study demonstrated the detection of ovarian cancer at 78/80% sensitivity with 100% specificity, offering the potential for a much more effective detection of ovarian cancer than traditional techniques. A larger RNA panel of markers used on a subset of patients yielded even higher sensitivity whilst retaining 100% specificity.
09/23/15 01:15 PMNewly Published Study Shows Parsortix Cell Separation System is Effective at Isolating Circulating Tumor Cells for Metastatic Cancer - [Business Wire] - Research conducted at Barts Cancer Institute, Queen Mary University, London, published today in PLOS ONE demonstrates that the Parsortix Cell Separation System from ANGLE plc, showed comparable speed – approximately two hours – in capturing circulating tumor cells for prostate cancer compared to bead-based epithelial cell adhesion molecule antibody CTC capturing systems, while also showing improved ...
09/17/15 11:12 AMJeff Howell: How to get rid of rust spots and convert a basement -
09/09/15 05:36 AMBreast Cancer Liquid Biopsy Results Presented At World CDx Conference In Boston - [PR Newswire] - Dr Julie E. Lang, M.D., F.A.C.S., Associate Professor of Surgery, specialising in breast cancer and notably in molecular profiling of circulating tumor cells (CTCs) in breast cancer, will present results from USC's work with ANGLE's Parsortix system at today's World CDx Conference in Boston. USC have compared the RNA molecular results of a liquid biopsy using the Parsortix system (simple blood test) with those from the biopsy of metastatic sites (the secondary cancer locations) in metastatic breast cancer patients.
07/08/15 09:36 AMLeading Prostate Cancer Expert Dr Daniel Danila Appointed Scientific Adviser - [PR Newswire] - GUILDFORD, England, July 8, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company with pioneering products for cancer diagnostics, is pleased to announce the appointment ...
06/11/15 06:00 AMANGLE plc's Parsortix System Harvests CTCS In 100% Of Prostate Cancer Patients - [PR Newswire] - GUILDFORD, United Kingdom, June 11, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is delighted to announce new results from its key opinion leader, Barts Cancer Institute (BCI), investigating the clinical use of the Parsortix system in prostate cancer patients. Prostate cancer is the second most common cancer in men and the fourth most common overall. More than 1.1 million cases of prostate cancer were recorded in 2012, accounting for around 8 per cent of all new cancer cases and 15 per cent in men (Source:World Cancer Research Fund International).
06/10/15 07:26 PMAngle posts positive prostate cancer treatment tests update -
06/03/15 06:00 AMANGLE plc appoints Jim Reuben Scientific Adviser - [PR Newswire] - GUILDFORD, England, June 3, 2015 /PRNewswire/ -- ANGLE plc (AGL.L) (ANPCY), the specialist medtech company, is pleased to announce the appointment of James M. Reuben, PhD, MBA, as a Scientific Advisor to the Company with immediate effect. Dr Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas.
06/03/15 06:00 AMANGLE plc appoints James M. Reuben as Scientific Advisor - [Business Wire] - ANGLE plc , a medical diagnostics company with pioneering products for cancer diagnostics and fetal health, is pleased to announce the appointment of James M. Reuben, PhD, MBA, as a Scientific Advisor to the company with immediate effect.
04/21/15 06:30 AMMedical University of Vienna Research Demonstrates Value of ANGLE plc’s ‘Blood Biopsy’ Technology - [Business Wire] - ANGLE plc , a UK-based medical diagnostics company with pioneering products for cancer diagnostics and fetal health, announce a poster presentation by researchers from the Medical University of Vienna detailing the utility of its lead product, the Parsortix cell separation system, in the detection of ovarian and breast cancer.
04/20/15 04:59 AMResults From The Sidney Kimmel Cancer Center At Thomas Jefferson University - [PR Newswire] - The results are being published as a poster at the American Association for Cancer Research Annual Meeting 2015 being held in Philadelphia ("AACR"). AACR is one of the world's largest and most influential cancer conferences. The poster can be downloaded from the ANGLE website here http://www.angleplc.com/the-parsortix-system/download-files/. A key challenge in investigating the metastatic process and improving the therapeutic benefit of cancer treatment is the heterogeneity (genetic variability) of the cancer cells. There are major potential benefits if circulating tumour cells (CTCs) can be harvested from patient blood and then processed individually one-by-one as intact cells for analysis. Technically this requires a high performance CTC capture and harvesting system that provides harvested CTCs in a form capable of then being processed by a single cell analysis system.
03/16/15 11:59 AMS&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports - [PR Newswire] - NEW YORK, March 16, 2015 /PRNewswire/ -- S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on ANGLE Plc. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalized cancer care.
02/16/15 12:34 PMANGLE plc ("Angle" or "the Company") Collaboration With MD Anderson Cancer Center On Colorectal Cancer - [PR Newswire] - GUILDFORD, England, Feb. 16, 2015 /PRNewswire/ -- ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce a collaboration with the MD Anderson Cancer Center to investigate the clinical use of ANGLE's Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is one of the world's most respected centres devoted exclusively to cancer patient care, research, education and prevention. MD Anderson was created in 1941 as part of The University of Texas System. United States News & World Report's "Best Hospitals" survey has ranked MD Anderson as one of the nation's top two cancer centres every year since the survey began in 1990.
About ANGLE plc

ANGLE plc logoANGLE plc is a United Kingdom-based holding company. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its lead product is Parsortix cell separation system, which can capture circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy enables the investigation of mutations in the patient's cancer for personalized cancer care. The Parsortix GEN3 Cassette is able to capture circulating tumor cells in cancer patient blood and works with a variety of cancers, including ovarian, prostate, breast, lung, colorectal, pancreatic and renal. The Company manages any overseas research, development (R&D), sales, and marketing from the United Kingdom segment. The Company's subsidiaries include ANGLE Europe Limited, ANGLE North America Inc, ANGLE Technology Limited, ANGLE Partnerships Limited and ANGLE Technology Licensing Limited.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AGL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.88
  • 50 Day Moving Average: $65.36
  • 200 Day Moving Average: $66.93
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $35.39M
  • Current Quarter EPS Consensus Estimate: $-8.50 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha